New Nanoparticles Developed to Protect Liver from Cisplatin Damage

Researchers have developed novel nanophytosomes designed to protect the liver from damage caused by cisplatin, a common chemotherapy drug. These nanoparticles co-load two key compounds: glycyrrhetinic acid and alpha-lipoic acid. The study focused on evaluating the efficacy of these co-loaded nanophytosomes through in vitro testing. The goal of this strategy is to mitigate the hepatocellular damage, or liver cell damage, that can result from cisplatin treatment. Cisplatin is a widely used platinum-based chemotherapy agent effective against various cancers. However, its use is often limited by significant side effects, including severe liver toxicity. Glycyrrhetinic acid, derived from licorice root, and alpha-lipoic acid, a potent antioxidant, are known for their protective properties. By encapsulating these compounds within nanophytosomes, the researchers aim to deliver them more effectively to the liver and enhance their protective effects. The in vitro evaluation assessed the ability of these nanophytosomes to reduce liver cell death and inflammation when exposed to cisplatin. This development represents a potential advancement in supportive care for cancer patients undergoing chemotherapy, aiming to improve treatment outcomes and patient quality of life by managing a critical side effect.